Most neurotech companies spend years on R&D and months on go-to-market. We build launch strategies for brain-computer interfaces, neurostimulation devices, and cognitive assessment platforms that account for clinical adoption, hospital procurement, and payer dynamics.

The Problem

Your launch plan is a spreadsheet, not a strategy

Many neurotech companies approach commercialization as a checklist — build a website, hire a sales rep, go to a conference. That works for SaaS. It doesn't work when your buyer is a hospital system with a 12-month procurement cycle, a value analysis committee, and a clinical champion who needs to be educated on your technology before they'll fight for budget. Without a structured GTM strategy, you burn cash on the wrong activities and miss your launch window.

You don't know which market segment to attack first

Neurotech products often have multiple potential applications — clinical research, direct patient care, enterprise wellness, defense. Trying to serve all of them at launch is a recipe for diluted messaging and scattered sales efforts. The most successful neurotech launches pick one beachhead segment, dominate it, and expand. But making that choice requires market analysis, customer development, and commercial modeling that most R&D-focused teams haven't done.

Your pricing doesn't reflect your value or your market

Neurotech pricing is uniquely complex. Are you selling a device, a subscription, a per-procedure fee, or a platform license? Does your buyer pay out of pocket, get reimbursed, or budget from a capital expenditure line? Most neurotech companies price based on cost-plus or competitor benchmarks without understanding willingness to pay, reimbursement dynamics, or the total economic value they create for the buyer. Getting pricing wrong at launch is expensive to fix.

Your sales process doesn't match how neurotech buyers actually buy

Enterprise neurotech sales involve multiple stakeholders — the clinician who evaluates the technology, the administrator who controls the budget, the IT team that assesses integration, and sometimes a payer who needs to authorize reimbursement. A standard sales process that targets one buyer and runs a linear funnel doesn't work here. You need a multi-threaded approach built for consensus-driven purchasing, and most neurotech startups haven't designed one.

How We Help

We start with market segmentation and beachhead selection. Using customer interviews, competitive analysis, and market sizing, we identify the segment where you have the strongest product-market fit, the shortest sales cycle, and the clearest path to reference customers. For neurotech companies, this often means choosing between clinical research institutions, specific hospital departments, outpatient clinics, or direct-to-consumer channels. We make the case for one and build the plan around it.

Pricing and packaging strategy comes next. We analyze your value proposition from the buyer's perspective — what clinical or operational problem you solve, what the alternative costs, and how the buyer's organization pays for solutions like yours. For FDA-cleared devices, we map reimbursement pathways and CPT codes. For research tools, we model per-seat and per-site licensing. The output is a pricing architecture that maximizes revenue capture while removing friction from the buying process.

We then build the sales playbook. This isn't a generic sales process — it's a neurotech-specific engagement model that maps every stakeholder in the buying process, defines the value proposition for each one, and sequences the outreach. For hospital sales, that means clinical champion development, value analysis committee preparation, and procurement navigation. We build the talk tracks, objection handlers, and competitive positioning your sales team needs to run the process confidently.

Channel strategy defines how you reach your market at scale. Direct sales, distributor partnerships, OEM relationships, and digital channels all play different roles depending on your segment and price point. We evaluate each channel against your unit economics and build a phased channel rollout that matches your team size and budget. Most neurotech companies need a mix of direct sales for early adopters and channel partnerships for scale.

Marketing and demand generation planning connects to the sales playbook. We define the content, events, and campaigns that fill the top of your funnel and nurture prospects through the long neurotech buying cycle. Conference strategy is a significant component — which events, what format, how to turn a booth visit into a qualified opportunity. We also build the digital presence that supports the sales process, because every neurotech buyer is going to research you online before they take a meeting.

Launch execution planning puts dates, owners, and budgets against every initiative. We build the 90-day launch calendar with weekly milestones, define the team structure needed to execute, and establish the metrics that tell you whether the GTM is working. This includes contingency planning — what you do if the first segment is slower than expected, if a competitor launches first, or if reimbursement takes longer to secure.

Post-launch, we establish the commercial operating rhythm — pipeline reviews, win/loss analysis, and quarterly strategy adjustments. The GTM plan isn't static. It evolves based on what you learn from your first customers, and we build the feedback loops that capture those insights and feed them back into strategy.

What we deliver

Market segmentation and beachhead analysis — segment evaluation, ICP definition, and market entry recommendation with supporting data
Pricing and packaging strategy — pricing architecture, reimbursement mapping, and competitive pricing analysis
Sales playbook — stakeholder maps, value propositions by buyer persona, talk tracks, objection handling, and competitive positioning
Launch plan — 90-day execution calendar, channel strategy, marketing plan, budget allocation, and success metrics

The neurotech companies that commercialize successfully don't just have a better product — they have a go-to-market plan that accounts for the fact that their buyer needs 6 internal approvals, a clinical evidence review, and an IT security assessment before they can say yes. Build for that reality or burn your runway learning it the hard way.

Our Methodology

Our GTM sprint runs 90 days with a clear phase structure. Days 1-30 are research and strategy: customer interviews, competitive analysis, market sizing, and strategic choices about segmentation, pricing, and channels. We pressure-test every assumption with real buyer feedback, not just internal hypotheses. By day 30, you have a documented GTM strategy that your board can evaluate and your team can execute.

Days 31-60 are playbook development and pre-launch preparation. We build the sales tools, marketing materials, and operational infrastructure needed to execute the strategy. For neurotech companies, this phase often includes developing clinical evidence summaries, regulatory-compliant marketing claims, and value analysis committee presentations. Everything is built to be used, not just read.

Days 61-90 are launch execution and optimization. We activate the plan, measure early results, and adjust in real time. The first customers in a neurotech launch are the most important — they become your reference accounts, your case studies, and your proof of concept for the next wave of buyers. We make sure those early engagements are managed strategically, not just transactionally.

How We Work

A GTM engagement involves a senior strategist and market researcher for the first 30 days, expanding to include sales enablement and marketing specialists during execution. Your time commitment is 5-8 hours per week from your CEO and commercial lead in month one for strategy sessions and customer interviews, dropping to 2-3 hours per week during execution.

The cadence is intensive by design: weekly strategy sessions in month one, bi-weekly execution reviews in months two and three, daily standups during launch week. Neurotech launches have a narrow window around conferences and regulatory milestones, and the cadence reflects that urgency.

We work alongside your team and agencies, providing the strategic layer that coordinates commercial activity. If you don't have a sales team yet, we help you define the first hire and support recruiting. If you have agency relationships, we ensure their work connects to the GTM strategy.

Expect honest assessments of market readiness. If your product isn't ready for commercial launch, we'll tell you and help prioritize pre-launch activities. The worst thing a neurotech company can do is launch prematurely and burn through their early market.

Clear market entry strategy with defined beachhead segment, pricing, and channel approach
Sales-ready organization with playbooks, tools, and processes built for neurotech buying cycles
Measurable launch performance with pipeline generation, conversion metrics, and revenue trajectory tracking

If your neurotech company needs go-to-market leadership, we should talk.

Expand your marketing team output with our experts

Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.

Frequently asked questions

How much does go-to-market cost for neurotech companies?

A full GTM engagement runs $100K-$250K depending on scope and execution support. For a neurotech company about to launch, that's typically less than one quarter of unfocused sales and marketing spend. The strategy work pays for itself by preventing the six-figure mistakes first-time launchers commonly make.

How long before we see results from go-to-market?

You'll have an executable strategy in 30 days and launch-ready materials in 60. Revenue results depend on your sales cycle — neurotech enterprise deals take 6-18 months, so pipeline generation starts in the first quarter and closed revenue follows your market's natural buying timeline. The strategy's value is in compressing that timeline as much as possible and ensuring you're not wasting cycles on unqualified opportunities.

How does the go-to-market team integrate with our existing staff?

We work directly with your CEO, head of commercial, and any sales or marketing hires. We're not building a parallel team — we equip your team with strategy, tools, and playbooks. If you're pre-hire, we help define roles and can participate in interviews. The goal is to build capability, not dependency.

What makes Winston Francois different from a traditional go-to-market agency?

We've built GTM plans for companies selling into regulated markets with multi-stakeholder buying. The standard SaaS GTM playbook fails in neurotech. We understand FDA timelines, clinical champion development, value analysis committees, and reimbursement strategy. We also stay through execution — most strategy firms hand you a deck and wish you luck.

How do you measure ROI from a go-to-market engagement?

Primary metrics are pipeline generated, qualified opportunity conversion rate, and time-to-first-revenue. We also track leading indicators: number of clinical champion conversations, value analysis committee submissions, and sales cycle stage progression. The measurement framework is built into the GTM plan so you're tracking from day one, not trying to reconstruct results after the fact.

What type of neurotech company is the right fit for this service?

The ideal client has a product that's FDA-cleared or within 6-12 months of clearance, has raised at least Series A, and has either no commercial team or a small team needing strategic direction. If you're still in early R&D without a clear regulatory pathway, you're too early. If you have a VP of Sales with a proven playbook, you need execution support, not strategy. The sweet spot is the transition from lab to market.